Table 2 Cumulative incidence of 3-month adverse clinical outcomes in AIS patients with and without diabetes
HbA1c (%) | Participants | Participants with adverse clinical outcomes | Cumulative incidence (95% CI) (%) |
|---|---|---|---|
Non-DM | |||
 Total | 896 | 220 | 24.6 (21.7–27.4) |
 HbA1c (< 5.5%) | 158 | 34 | 21.5 (15.0–28.0) |
 HbA1c (5.5%-6.0%) | 502 | 126 | 25.1 (21.3–28.9) |
 HbA1c (6.0%-6.5%) | 236 | 60 | 25.4 (19.8–31.0) |
DM | |||
 Total | 628 | 211 | 33.6 (29.9–37.3) |
 HbA1c (< 6.0%) | 60 | 27 | 45.0 (32.0–58.0) |
 HbA1c (6.0%-6.5%) | 90 | 27 | 30.0 (20.3–39.7) |
 HbA1c (6.5%-7.0%) | 181 | 61 | 33.7 (26.7–40.7) |
 HbA1c (≥ 7.0%) | 297 | 96 | 32.3 (27.0–37.7) |